A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
← catalyst calendarSponsored by BioMarin Pharmaceutical (industry) · BMRN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
100estimated
Sites
47
Countries
Australia, France, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-21 | actual | When the study began enrolling |
| Primary completion | Jun 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2036 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Idiopathic Short Stature
Interventions
- Drug: Vosoritide Injection
- Drug: Human Growth Hormone
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in Annualized Growth Velocity (AGV)
measured At 6 months
Change from baseline in height
measured At 4 years
Change from baseline in height Z-score
measured At 4 years
Permalink · BMRN's whole pipeline · Catalyst calendar · Every registered study · What changed